KIAA1377 Inhibitors
The class of KIAA1377 inhibitors comprises a collection of chemicals that exert their influence on KIAA1377 expression and function through targeted modulation of specific cellular signaling pathways. These compounds offer a controlled approach for investigating the regulatory mechanisms of KIAA1377 in various cellular processes. One group of inhibitors includes BAY 11-7082, SB203580, SP600125, U0126, LY294002, Rapamycin, PD98059, AS601245, Wortmannin, Torin 1, AZD6244, and PI-103. These compounds indirectly modulate KIAA1377 by targeting distinct signaling pathways, such as NF-κB, p38 MAPK, JNK, MAPK/ERK, PI3K/AKT, and mTOR. By inhibiting these pathways, the inhibitors induce downstream alterations that impact KIAA1377 expression and function. BAY 11-7082, for instance, targets the NF-κB pathway, while SB203580 and AS601245 dampen the p38 MAPK pathway. SP600125 inhibits JNK, U0126 and PD98059 target MAPK/ERK, and LY294002 and Wortmannin inhibit PI3K, influencing KIAA1377 through these pathways. Rapamycin, Torin 1, and AZD6244 act on the mTOR pathway, further expanding the repertoire of controlled tools for studying KIAA1377 modulation.
These inhibitors, by virtue of their specific interactions with key signaling pathways, provide researchers with the means to dissect the intricate regulatory network of KIAA1377. Understanding how these compounds impact KIAA1377 in cellular processes sheds light on the protein's role in diverse biological contexts. The class of KIAA1377 inhibitors, with its diverse array of compounds and targeted pathways, thus serves as an indispensable resource for unraveling the complexities of KIAA1377
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082, an IKK inhibitor, indirectly modulates KIAA1377 by inhibiting the NF-κB signaling pathway. This leads to altered downstream events, impacting KIAA1377 expression and function. By targeting the NF-κB pathway, BAY 11-7082 provides a specific means to study KIAA1377 modulation in cellular processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, indirectly influences KIAA1377 by dampening the p38 MAPK pathway. This leads to altered downstream events, impacting KIAA1377 expression and function. By inhibiting the p38 MAPK pathway, SB203580 provides a controlled approach for studying KIAA1377 modulation in cellular processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly modulates KIAA1377 through inhibition of the JNK signaling pathway. This alters downstream events, impacting KIAA1377 expression and function. By targeting the JNK pathway, SP600125 offers a specific means to study KIAA1377 modulation and its role in cellular processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly modulates KIAA1377 by inhibiting the PI3K/AKT pathway. This leads to altered downstream events, impacting KIAA1377 expression and function. By targeting the PI3K/AKT pathway, LY294002 offers a specific means to study KIAA1377 modulation and its role in cellular processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly influences KIAA1377 by inhibiting the mTOR pathway. This disruption affects KIAA1377 expression and function. By specifically targeting the mTOR pathway, Rapamycin provides a controlled approach for studying KIAA1377 modulation in cellular processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, a MEK1 inhibitor, indirectly modulates KIAA1377 by inhibiting the MAPK/ERK pathway. This disruption affects KIAA1377 expression and function. By specifically targeting the MAPK/ERK pathway, PD98059 provides a controlled approach for studying KIAA1377 modulation in cellular processes. | ||||||
PI 3-Kγ Inhibitor | 648450-29-7 | sc-203191 | 5 mg | $76.00 | ||
AS601245, a p38 MAPK inhibitor, indirectly influences KIAA1377 by dampening the p38 MAPK pathway. This leads to altered downstream events, impacting KIAA1377 expression and function. By inhibiting the p38 MAPK pathway, AS601245 provides a specific means to study KIAA1377 modulation in cellular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly modulates KIAA1377 by inhibiting the PI3K/AKT pathway. This leads to altered downstream events, impacting KIAA1377 expression and function. By targeting the PI3K/AKT pathway, Wortmannin offers a specific means to study KIAA1377 modulation and its role in cellular processes. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $240.00 | 7 | |
Torin 1, a dual mTOR inhibitor, indirectly influences KIAA1377 by inhibiting the mTOR pathway. This disruption affects KIAA1377 expression and function. By specifically targeting the mTOR pathway, Torin 1 provides a controlled approach for studying KIAA1377 modulation in cellular processes. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI-103, a dual PI3K/mTOR inhibitor, indirectly influences KIAA1377 by inhibiting the PI3K/AKT/mTOR pathway. This leads to altered downstream events, impacting KIAA1377 expression and function. By targeting the PI3K/AKT/mTOR pathway, PI-103 offers a specific means to study KIAA1377 modulation and its role in cellular processes. | ||||||